SmithG., HendersonI.C.New treatments for breast cancer. Semin Oncol.1996; 23: 506–528.
2.
HolmesF.A., WaltersR.S., TheriaultR.L.Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst.1991; 83: 1797–1805.
3.
SwainS., HonigS., WaltonL.Phase II trial of paclitaxel (Taxol) as first line chemotherapy for metastatic breast cancer (MBC). Proc Annu Meet Am Soc Clin Oncol.1995; 14: A132.
4.
ReichmanB.S., SeidmanA.D., CrownJ.P.Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol.1993; 11: 1943–1951.
5.
SeidmanA.D., NortonL., ReichmanB.S.Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer. Semin Oncol.1993; 20(suppl); 40–45.
6.
SeidmanA.D., ReichmanB.S., CrownJ.P.Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol.1995; 13: 1152–1159.
7.
MamounasE., BrownA., FisherB.Three-hour high -dose Taxol infusion following standard Adriamycin-cyclophosphamide in advanced or high-risk breast cancer: an NSABP feasibility study. Proc Annu Meet Am Soc Clin Oncol.1995; 14: A127.
8.
O'ReillyS.E., GelmonK.A.Biweekly paclitaxel and cisplatin: a phase I/II study in the first-line treatment of metastatic breast cancer. Semin Oncol.1995; 22(suppl 6): 109–111.
9.
NabholtzJ.M., GelmonK., BontenbalM.Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol.1996; 14: 1858–1867.
10.
GianniL., MunzoneE., CapriG.Paclitaxel in metastatic breast cancer. a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst.1995; 87: 1169–1175.
11.
HolmesF.A.Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review. Semin Oncol.1996; 23(suppl 11): 45–56.
12.
GianniL., MunzoneE., CapriG.Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol.1995; 13: 2688–2699.
13.
GianniL., CapriG., TarenziE.Efficacy and cardiac effects of 3-h paclitaxel (P) plus bolus doxorubicin (DOX) in women with untreated metastatic breast carcinoma. Proc Annu Meet Am Soc Clin Oncol.1996; 15: A116.
14.
GianniL., GiuseppeC.Experience at the Istituto Nazionale Tumori with paclitaxel in combination with doxorubicin in women with untreated breast cancer. Semin Oncol.1997; 24(suppl 3): S3-1–S3-3.
15.
GehlJ., BoesgaardM., PaaskeT.Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol.1996; 7: 687–693.
16.
SchwartsmannG., MenkeC.H., CaleffiM.Phase II trial of Taxol (T), doxorubicin (D) plus G-CSF in patients (pts) with metastatic breast cancer (MBC). Proc Annu Meet Am Soc Clin Oncol.1996; 15: A146.
17.
FrassinetiG.L., ZoliW., TienghiA.The sequential administration of combined doxorubicin and paclitaxel in the treatment of advanced breast cancer. Semin Oncol.1996; 23(suppl 12): 22–28.
18.
CazapE., VentrigliaM., RubioG.Taxol (T) plus doxorubicin (D) in the treatment of metastatic breast cancer (MBC) in ambulatory patients (pts). Proc Annu Meet Am Soc Clin Oncol.1996; 15: A146.
19.
BishopJ.F., DewarJ., TattersallM.H.A randomized phase III study of Taxol (paclitaxel) vs CMFP in untreated patients with metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol.1996; 15: A110.
20.
GelmonK.The taxoids: paclitaxel and docetaxel. Lancet.1994; 344: 1267–1272.
21.
ArbuckS.G.Paclitaxel: what schedule? What dose?J Clin Oncol.1994; 12: 233–236.
22.
ValeroV., BurrisHAIII, JonesS.E.Multicenter pilot study of taxotere in Taxol-resistant metastatic breast cancer (MBC). Proc Annu Meet Am Soc Clin Oncol.1996; 15: A107.
23.
TrudeauM.E., EisenhauerE.A., HigginsB.P.Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol.1996; 14: 422–428.
24.
FumoleauP., ChevallierB., KerbratP.A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Ann Oncol.1996; 7: 165–171.
25.
ChevallierB., FumoleauP., KerbratP.Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol.1995; 13: 314–322.
26.
HudisC.A., SeidmanA.D., CrownJ.P.A.Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol.1996; 14: 58–65.
27.
DierasV., ChevallierB., KerbratP.A multicentre phase II study of docetaxel 75 mg/m2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. Br J Cancer.1996; 74: 650–656.
28.
RavdinP.M., BurrisHAIII, CookG.Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol.1995; 13: 2879–2885.
29.
ten Bokkel HuininkW.W., ProveA.M., PiccartM.A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol.1994; 5: 527–532.
30.
ValeroV., HolmesF.A., WaltersR.S.Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol.1995; 13: 2886–2894.
31.
TaguchiT., AdachiI., EnomotoK.Docetaxel (RP56976) in advanced or recurrent breast cancer early and late phase II clinical studies in Japan. Proc Annu Meet Am Soc Clin Oncol.1994; 13: A87.
32.
EisenhauerE.A.Docetaxel: current status and future prospects. J Clin Oncol.1995; 13: 2865–2868.
33.
GruiaG., MissetJ.L., GiachettiS.A phase I-II study of Taxotere (TXTR) in combination with Adriamycin (AD) as first line chemotherapy (CT) in patients with metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol.1995; 14: A140.
34.
BurrisHAIII, FieldsS., PeacockN.Docetaxel (Taxotere) in combination: a step forward. Semin Oncol.1995; 95(suppl 6): 35–40.
35.
BourgeoisH., GruiaG., DierasV.Docetaxel (D) in combination with doxorubicin (Dx) as 1st line CT of metastatic breast cancer (MBC): a phase I dose finding study. Proc Annu Meet Am Soc Clin Oncol.1996; 15: A148.
36.
CagnoniP.J., StemmerS.M., MatthesS.Phase I trial of high dose paclitaxel (TAXOL) cyclophosphamide (CPA) and cisplatin (cDDP) with autologous hematopoietic progenitor cell (AHPC) rescue. Proc Annu Meet Am Soc Clin Oncol.1995; 14: A477.
37.
ZimmermanT.M., MickR., GrinblattD.L.High-dose cyclophosphamide (CY), thiotepa (TTP) with escalating continuous infusion Taxol (TXL) and autologous stem cell rescue (ASCR) for metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol.1995; 14: A328.
38.
DavidsonN.G.Single-agent paclitaxel as first-line treatment of metastatic breast cancer: the British experience. Semin Oncol.1996; 23(suppl 11): 6–10.
39.
GeyerC.E.Jr, GreenS.J., MoinpourC.A phase II trial of paclitaxel in patients with metastatic refractory carcinoma of the breast: a Southwest Oncology Group (SWOG) study. Proc Annu Meet Am Soc Clin Oncol.1996; 15: A107.
40.
BonneterreJ., Tubiana-HulinM., CholletP.Taxol (paclitaxel) 225 mg/m2 by 3-hour infusion without G-CSF as a first line therapy in patients with metastatic breast cancer (MBC). Proc Annu Meet Am Soc Clin Oncol.1996; 15: A128.
41.
NortonL.Kinetic concepts in the treatment of breast cancer. Recent Results Cancer Res.1993; 127: 1–6.
42.
PeretzT., SulkesA., CholletP.A multicenter randomized study of two schedules of paclitaxel in patients with advanced breast cancer. Eur J Cancer. 1995; 31A(suppl 5): S75.
43.
RowinskyE.K.The taxanes: dosing and scheduling considerations. Oncology.1997. In press.
44.
BelottiD., VerganiV., DrudisT.The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res.1996; 2: 1843–1849.
45.
McCaskill-StevensW.J., SparanoJ.A., CobleighM.Pilot trial of alternating paclitaxel and doxorubicin in advanced breast cancer. Breast J.1997; 3: 19–24.
46.
HolmesF., NewmanR., MaddenV.Schedule dependent pharmacokinetics (PK) in a phase I trial of Taxol and doxorubicin as initial chemotherapy for metastatic breast cancer. Ann Oncol Suppl.1994; 5: 197. Abstract.
47.
O'ShaughnessyJ., FishermanJ., CowanK.Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer. Semin Oncol.1994; 21: (suppl): 819–823.
48.
AmadoriD., FrassinetiG.L., ZoliW.A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer. Semin Oncol.1996; 23(suppl 11): 16–22.
49.
LüftnerD., MergenthalerH.G., GrunewaldR.Paclitaxel in a weekly fractionated schedule in advanced breast cancer. Proc Annu Meet Am Soc Clin Oncol.1996; 15: A150.
50.
HolmesF.A., ValeroV., WaltersR.Phase III trial of paclitaxel (P) administered over 3- or 96-hr for metastatic breast cancer (MBC). Proc Annu Meet Am Soc Clin Oncol.1996; 15: A91.
51.
BreierS., LebedinskyC., PelayesL.Preliminary analysis, weekly paclitaxel (P) in previously treated patients (pts) with metastatic disease. Proc Annu Meet Am Soc Clin Oncol.1996; 15: A182.
52.
AkerleyW., ChoyH., GlantzV.Weekly paclitaxel for metastatic non-small cell lung cancer (NSCLC): a phase I trial. Proc Annu Meet Am Soc Clin Oncol.1996; 15: A377.
53.
FennellyD., AghajanianC., ShapiroF.Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol.1997; 15: 187–192.
54.
LöfflerT.M., FreundW., LipkeJ.Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial. Semin Oncol.1996; 23(suppl 16): 32–34.
